Integrin α11 Inhibitors

Integrin α11 is a subtype of the integrin family, a group of cell surface receptors that play a crucial role in cell adhesion and signal transduction. Direct inhibition of Integrin α11 is challenging due to the complexity of integrin-mediated interactions and the lack of specific small molecule inhibitors targeting this subtype. The inhibitors listed above primarily target other integrin subtypes but may indirectly influence Integrin α11. For example, Cilengitide are designed to antagonize specific integrins (e.g., αv integrins), but they can also affect the broader integrin signaling network, potentially impacting α11 functions. This indirect effect might stem from the shared signaling pathways or compensatory mechanisms within the integrin family.

Glycoprotein IIb/IIIa inhibitors like Tirofiban and Eptifibatide, primarily known for their role in inhibiting platelet aggregation, demonstrate the interconnected nature of integrin-mediated processes. While these drugs are specific to certain integrin subtypes involved in platelet function, they highlight the potential for cross-talk within integrin signaling pathways. Additionally, peptide inhibitors like ATN-161, which targets α5β1 integrin, and antibodies like Volociximab and Abituzumab, targeting various αv-class integrins, represent a strategy of influencing integrin functions indirectly. These compounds, by modulating the activity of closely related integrins, could impact the cellular processes where Integrin α11 is involved.